Oxycodone News and Research RSS Feed - Oxycodone News and Research

Researchers developing opioid vaccines to help prevent overdose fatalities

Researchers developing opioid vaccines to help prevent overdose fatalities

In 2014, the number of deaths from opioid overdoses in the U.S. jumped to its highest level on record. The spike brought national attention to the epidemic and the awareness that new interventions are needed. [More]
New vaccine shows potential to decrease risk of fatal opioid overdose

New vaccine shows potential to decrease risk of fatal opioid overdose

Scientists at The Scripps Research Institute have developed a vaccine that blocks the pain-numbing effects of the opioid drugs oxycodone and hydrocodone in animal models. [More]
Study finds increasing incidence of hospitalizations for prescription opioid poisonings in children and teens

Study finds increasing incidence of hospitalizations for prescription opioid poisonings in children and teens

The overall incidence of hospitalizations for prescription opioid poisonings in children and adolescents has more than doubled from 1997 to 2012, with increasing incidence of poisonings attributed to suicide or self-inflicted injury and accidental intent, according to a new study published online by JAMA Pediatrics. [More]
Urgent Matters announces recipients of Emergency Care Innovation of the Year Award

Urgent Matters announces recipients of Emergency Care Innovation of the Year Award

Urgent Matters, Philips Blue Jay Consulting, and Schumacher Clinical Partners are pleased to announce the winners of the Emergency Care Innovation of the Year Award, a competition to foster innovation in emergency departments nationwide. [More]
Wayne State receives NIH grant to study use of opioid addiction drug to fight relapse in recovering addicts

Wayne State receives NIH grant to study use of opioid addiction drug to fight relapse in recovering addicts

A team led by Wayne State University School of Medicine researcher Mark Greenwald, Ph.D., will use a four-year, $2,279,723 competitively renewed grant from the National Institute on Drug Abuse of the National Institutes of Health to explore whether the opioid addiction treatment medication buprenorphine can decrease the magnitude and/or duration of responses to stressors faced by recovering addicts. [More]
Quest Diagnostics analysis shows workforce drug use in U.S. reaches 10-year high

Quest Diagnostics analysis shows workforce drug use in U.S. reaches 10-year high

Following years of declines, the percentage of employees in the combined U.S. workforce testing positive for drugs has steadily increased over the last three years to a 10-year high, according to an analysis of nearly 11 million workforce drug test results released today by Quest Diagnostics, the world's leading provider of diagnostic information services. [More]
Buprenorphine implants could be effective option to treat adults with opioid dependence

Buprenorphine implants could be effective option to treat adults with opioid dependence

While buprenorphine has long been used to treat adults with opioid dependence, its efficacy can be hindered by lack of adherence to daily, sublingual (beneath the tongue) doses of the medication. [More]
New opioid use among older adults with COPD linked to increased risk for respiratory-related death

New opioid use among older adults with COPD linked to increased risk for respiratory-related death

Older adults with chronic obstructive pulmonary disease who start using opioids have a more than two-fold higher risk of dying from a respiratory-related complication compared to non-opioid users, St. Michael's Hospital researchers have found. [More]
ASA recommends parents to ask seven questions to child's physician anesthesiologist prior to surgery

ASA recommends parents to ask seven questions to child's physician anesthesiologist prior to surgery

Millions of children have surgery every year - for everything from tonsil removal to correction of a heart defect - and understandably parents are often anxious about their child's safety and comfort. [More]
Programs to prevent prescription drug misuse may be underused, study reveals

Programs to prevent prescription drug misuse may be underused, study reveals

Misuse of prescription pain medications remains a major public health problem -- but programs to prevent it may be underused, according to a study in the July issue of the Journal of Studies on Alcohol and Drugs. [More]
Short-term use of opioids implicated in protracted pain, new study finds

Short-term use of opioids implicated in protracted pain, new study finds

Painkillers such as morphine, oxycodone and methadone could actually prolong and increase pain even after only a few days’ use, according to research conducted on rats by scientists at the University of Colorado Boulder in the US. [More]
Brief opioid exposure can cause increase in chronic pain

Brief opioid exposure can cause increase in chronic pain

The dark side of painkillers - their dramatic increase in use and ability to trigger abuse, addiction and thousands of fatal overdoses annually in the United States is in the news virtually every day. [More]
Study: Disparities in pain management may be partly attributed to bias

Study: Disparities in pain management may be partly attributed to bias

Research has documented that black Americans are systematically undertreated for pain relative to white Americans, likely due to both the over-prescription and over-use of pain medications among white patients and the under-prescription of pain medications for black patients. [More]
Opioids could be dangerous, deadly at high doses

Opioids could be dangerous, deadly at high doses

Most people know that heroin is a dangerous drug, but its cousins, the legal, pharmaceutical opioids, such as codeine or hydrocodone, must be safe, right?Not so fast.Opioids—which include the illegal drug heroin as well as prescription medications, including hydrocodone (such as Vicodin), oxycodone (such as OxyContin and Percocet), morphine and codeine—can be dangerous, even deadly, at high doses. [More]
FDA announces required class-wide safety labeling changes for IR opioid pain medications

FDA announces required class-wide safety labeling changes for IR opioid pain medications

In a continuing effort to educate prescribers and patients about the potential risks related to opioid use, the U.S. Food and Drug Administration today announced required class-wide safety labeling changes for immediate-release (IR) opioid pain medications. Among the changes, the FDA is requiring a new boxed warning about the serious risks of misuse, abuse, addiction, overdose and death. [More]
Changes in substance use policies can significantly impact life expectancy

Changes in substance use policies can significantly impact life expectancy

While average life expectancy has been rising steadily in most countries over the past century, new research led by the Centre for Addiction and Mental Health shows that life expectancy declined significantly and rapidly in three countries where policy changes increased access to prescription opioids, alcohol or illicit drugs. [More]
New reference guide can help HIV care providers treat chronic pain

New reference guide can help HIV care providers treat chronic pain

Recent studies suggest many individuals with HIV have chronic pain. Estimates range from 39 percent all the way to 85 percent. Chronic pain is an important comorbid condition in individuals with HIV, as it is common and causes substantial disability. [More]
New vaccine strategy may curb addiction, prevent fatal overdoses

New vaccine strategy may curb addiction, prevent fatal overdoses

With use of synthetic opioid "designer drugs" on the rise, scientists from The Scripps Research Institute have a new strategy to curb addiction and even prevent fatal overdoses. [More]
Long-term use of opioids increases risk of new-onset depression

Long-term use of opioids increases risk of new-onset depression

Opioids may cause short-term improvement in mood, but long-term use imposes risk of new-onset depression, a Saint Louis University study shows. [More]
DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI). [More]
Advertisement
Advertisement